Skip to content
Anti-TNF prescribing survey
1.
What is your current role?
General gastroenterologist
Gastroenterologist with a particular interest in IBD
General Surgeon
General Physician
Gastroenterology Trainee
Other
2.
With regard to infliximab prescribing for IBD. Do you escalate dosing beyond those approved by Special authority criteria (5mg/Kg 8 weekly with provision for high dose re-induction)?
Yes, often (>25% of patients) at higher than approved doses
Yes, occasionally (1-25% of patients) at higher than approved doses
I only use approved re-induction regimes to dose escalate
No, only prescribe at standard dosing schedule
No, my pharmacy will not allow escalated dosing
3.
If you escalate dosing of infliximab, what guides this decision? (select as many as apply)
Clinical symptoms alone
Therapeutic drug monitoring (TDM) alone
Biomarkers alone
4.
If you prescribe escalated doses of infliximab, beyond special authority criteria, how do you access this?
Hospital pharmacy supply dosing as prescribed
Janssen supply extra dosing via compassionate access
Other (please specify)
5.
With regard to adalimumab dosing, do you ever prescribe >40mg sc weekly?
Yes
No
6.
If yes please comment on how you access this?
7.
Do you have any comments on access to anti-TNF dose escalation in New Zealand?